TTK Healthcare Ltd

TTK Healthcare Ltd maintains a strong liquidity position with a current ratio of 5.35, indicating a robust ability to meet short-term obligations. The company's cash and equivalents amount to INR 7.75 billion, significantly exceeding its total liabilities of INR 2.05 billion, and its long-term debt is minimal at INR 228.11 million. The liquidity risk is assessed as low, supported by the absence of immediate filing-based liquidity flags. Profitability metrics show a return on equity (ROE) of 1.83% and a return on assets (ROA) of 1.51%, which are below the industry median for pharmaceutical companies. The net income of INR 182.72 million is derived from a gross profit of INR 970.71 million, with operating income at INR 90.98 million. These figures suggest a relatively low margin structure compared to industry peers. The company's revenue is concentrated in its core segments, with diagnostics, medical devices, and hospital services forming the primary revenue streams. No specific geographic breakdown is provided, but the company operates primarily in India. The lack of detailed geographic exposure data limits the assessment of regional concentration risk. TTK Healthcare Ltd's growth trajectory is modest, with no significant revenue growth or decline reported in the latest financial period. The company's capital expenditure of INR 103.83 million reflects ongoing investment in infrastructure and operations. However, the operating cash flow is negative at INR 49.43 million, indicating potential challenges in generating cash from operations. Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.02 suggests a conservative capital structure. There is no indication of near-term dilution pressure, and the dilution risk is assessed as low. Recent events include the latest financial filing, which provides updated financial metrics and operational performance. No significant regulatory or legal events were reported in the latest filings, and the company's risk assessment remains stable.